jetcityimage/iStock Editorial via Getty Images
- Eli Lilly (NYSE:LLY) has raised expectations for its experimental weight loss pill, orforglipron, capitalizing $548.1M in pre-launch inventory in 2024 for the next-gen drug ahead of a potential regulatory nod next year.
- The line item indicated in the Indiana-based drugmaker’s